Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last --
Change Today 0.00 / 0.00%
Volume 0.0
WOCKPHARMA On Other Exchanges
WOCKPHARMA is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

wockhardt ltd (WOCKPHARMA) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for WOCKHARDT LTD (WOCKPHARMA)

Related News

No related news articles were found.

wockhardt ltd (WOCKPHARMA) Related Businessweek News

No Related Businessweek News Found

wockhardt ltd (WOCKPHARMA) Details

Wockhardt Limited, a pharmaceutical and biotechnology company, together with its subsidiaries, manufactures and markets pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs), and vaccines. It provides pharmaceutical products in various dosage forms, such as sterile injectables and lyophilised products in the therapeutic areas of anti-infectives, cardiology, dermatology, diabetology, neurology, pain management, respiratory, and other areas. The company offers generic products that comprise injectables, including cephalosporins and non-cephalosporins; and value-added generics. Its biopharmaceutical products include Glargine that is recombinant long-acting insulin; Wosulin, which is r-DNA insulin; Wepox, a recombinant erythropoietin is used in the treatment of anaemia caused by cancer and chronic renal failure; and Biovac-B, a hepatitis B vaccine. The company also provides contract manufacturing and packaging services for sterile injectables, lyophilisation, solid dose, liquids/ointments/creams, sachets and powders, and specialized products; API manufacturing services; and contract research services. Its research activities comprise pharmaceutical formulations, biopharmaceutical bulk and formulations, novel drug delivery systems, new drug discovery programs, and process engineering for APIs. The company develops various molecules primarily in the area of anti-infectives, which include WCK 771 that is in Phase II human clinical trials for the treatment of staphylococcal infections; and WCK 2349, WCK 4873, and WCK 4086 lead molecules, which are under pre-clinical trials. Wockhardt Limited offers its products in India, the United States, Europe, and other countries. The company was incorporated in 1999 and is headquartered in Mumbai, India. Wockhardt Limited is a subsidiary of Khorakiwala Holdings and Investments Private Limited.

8,600 Employees
Last Reported Date: 08/19/14
Founded in 1999

wockhardt ltd (WOCKPHARMA) Top Compensated Officers

Managing Director, Executive Director, Member...
Total Annual Compensation: 13.3M
Founder, Executive Chairman, Group Chief Exec...
Total Annual Compensation: 4.8M
Executive Director, Member of Share Allotment...
Total Annual Compensation: 13.3M
Compensation as of Fiscal Year 2014.

wockhardt ltd (WOCKPHARMA) Key Developments

Wockhardt Ltd. to Shift its Registered Office from Mumbai to Aurangabad

Wockhardt Ltd. announced that the shareholders of the company through postal ballot has approved a proposal of shifting of registered office of the company from Mumbai to Aurangabad, within the state of Maharashtra.

Wockhardt UK Ltd. Wins Multiple Awardees Contract for Supplying Generic Transition Pharmaceuticals

Wockhardt UK Ltd. won a multiple awardees contract award from The Secretary of State of Health acting as part of the Crown through the Commercial Medicines Unit (part of the Department of Health) for the supply of generic transition pharmaceuticals. The lowest offer is GBP 6.5 million and the high offer is GBP 7 million.

Wockhardt Ltd. Presents at India Investor Conference, Mar-02-2015 03:00 PM

Wockhardt Ltd. Presents at India Investor Conference, Mar-02-2015 03:00 PM. Venue: Trident Hotel, Bandra Kurla, C-56, G Block, Bandra Kurla Complex, Mumbai, Maharashtra, India. Speakers: Habil F. Khorakiwala, Founder, Executive Chairman, Group Chief Executive Officer, Chairman of Credit Facilities Committee, Chairman of Share Allotment Committee, Chairman of Esos Compensation Committee and Chairman of Corporate Social Responsibility (CSR) Committee.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
WPL:IN 1,700.55 INR 0.00

WOCKPHARMA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cadila Healthcare Ltd 1,734 INR 0.00
Cipla Ltd/India 680.40 INR 0.00
Endo International PLC $93.34 USD -1.77
Ipca Laboratories Ltd 661.60 INR 0.00
Torrent Pharmaceuticals Ltd 1,281 INR 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation WOCKPHARMA Industry Range
Price/Earnings 42.9x
Price/Sales 4.3x
Price/Book 5.6x
Price/Cash Flow 32.0x
TEV/Sales 3.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WOCKHARDT LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at